Lineage Cell Therapeutics(LCTX)
CARLSBAD, CABiotechnology
Focus: Lineage Cell Therapeutics is a public regenerative medicine biotech focused on cell therapy for spinal cord injuries and other conditions. The company operates as a clinical-stage developer with minimal revenue and high R&D burn.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
1
Should You Work at Lineage Cell Therapeutics?
AI assessmentBest suited for mission-driven scientists willing to accept higher financial risk for early-stage regenerative medicine innovation with meaningful social impact.
Why Work Here
- Pioneer regenerative medicine platform with multiple Phase 1/1-2 programs in spinal cord injury, a large unmet medical need
- Public company status provides equity upside potential and established governance infrastructure
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
5 total
LOE Risk
Protected
No near-term cliffs
Hiring
1 open
Revenue
$9M
FY2025
Pipeline & Clinical Trials
Magnetic Resonance Imaging
Spinal Cord InjuriesClinical Trials (1)
NCT05919563LTFU Study of Subjects Who Received GRNOPC1
N/AHelp build intelligence for Lineage Cell Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.